However, it has been reported that patients with nonalcoholic steatohepatitis (NASH)-mediated liver cancer may not benefit from anti-PD1 treatment; besides, NASH-related aberrant T-cell activation is a potential cause [6]. Here, PDCD1 is linked to liver cancer.